FDA approves atezolizumab with chemotherapy after surgery for stage III dMMR colon cancer
On 8 October 2026 the FDA approved Tecentriq (atezolizumab) with chemotherapy as adjuvant treatment for stage III colon cancer.
On 8 October 2026 the FDA approved Tecentriq (atezolizumab) with chemotherapy as adjuvant treatment for stage III colon cancer.
WHO’s latest Global Health Estimates put global life expectancy at 73.3 years in 2023, close to 73.4 in 2019.
The CDC reported on a botulinum toxin product not approved by the FDA that was used at a Colorado medical spa.
On 8 October 2026 WHO and partners launched a global roadmap on hypertensive disorders of pregnancy.
On 9 October 2026 WHO released a guide to help countries move from institutional to community-based mental health care.
On 7 October 2026 the FDA approved Tukysa (tucatinib) with trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer.
Saudi Arabia reported eight laboratory-confirmed MERS-CoV cases, including one death, between 1 January and 5 October 2026.
The Aesthetic Surgery Journal published a multicentre randomised study of Belotero Intense with lidocaine for lip augmentation.
In October 2026 the EMA's human medicines committee recommended making Nyxoid (naloxone) available without a prescription.
On 15 October 2026 the EMA's human medicines committee adopted a positive opinion extending the indication of AstraZeneca's H5N1 pandemic vaccine.
Nothing more to show